Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat versus standard of care in Fabry disease with left ventricular hypertrophy
NL-OMON54374Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Fabry disease (FD) comparing Venglustat with Standard of care Fabry therapy (2 arms). Primary endpoint: Slope of left ventricular mass index. Started May 2023; status: recruiting.
02
Drugs
venglustat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NL-OMON54374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54374.